Positive topline data in Phase 3 pivotal trials demonstrate that iDose TR (Glaukos) successfully achieved its pre-specified primary efficacy endpoints through three months, with

Apellis Pharmaceuticals has announced top-line data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the

Hoya Vision Care has shared the latest findings of the clinical application of the MiYOSMART spectacle lens, and its role in myopia management, at

Glaukos, the corporate founder and pioneer of micro-invasive glaucoma surgery (MIGS), has announced that more than one million iStent technologies have been implanted in